Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired several smaller pharmaceutical companies
|
| gptkbp:awards |
gptkb:National_Quality_Award
Top 100 Pharmaceutical Companies in China |
| gptkbp:CEO |
gptkb:Zhang_Jian
|
| gptkbp:certifications |
gptkb:ISO_9001
GMP_certified |
| gptkbp:communityInvolvement |
Participates in educational programs
Supports local health initiatives |
| gptkbp:environmentalImpact |
Sustainable manufacturing practices
Waste reduction initiatives |
| gptkbp:exportMarkets |
gptkb:North_America
gptkb:Southeast_Asia Europe |
| gptkbp:financialPerformance |
Consistent growth in revenue
Strong profit margins Increasing market share Positive cash flow High return on investment |
| gptkbp:focus |
Innovative drugs
Healthcare_products Generic_drugs |
| gptkbp:founded |
1992
|
| gptkbp:headquarters |
gptkb:Yiyang,_Hunan,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Yiyang Pharmaceutical Group
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
gptkb:China
|
| gptkbp:numberOfEmployees |
Over 5,000
|
| gptkbp:partnerships |
Collaborates with international pharmaceutical companies
|
| gptkbp:productLine |
Antibiotics
Vaccines Oncology drugs Nutraceuticals Cardiovascular drugs Vitamins and supplements Pain management drugs Dermatological products Gastrointestinal drugs Respiratory drugs Neurology drugs Hormonal drugs Traditional_Chinese_medicine_products Antidiabetic_drugs |
| gptkbp:products |
Prescription drugs
Biopharmaceuticals Over-the-counter drugs |
| gptkbp:researchAndDevelopment |
Invests heavily in R&D
|
| gptkbp:revenue |
Over 1 billion USD
|
| gptkbp:stockExchange |
gptkb:Shenzhen_Stock_Exchange
|
| gptkbp:stockSymbol |
002603
|
| gptkbp:subsidiary |
gptkb:Yiyang_Biopharmaceutical_Co.,_Ltd.
gptkb:Hunan_Yiyang_Pharmaceutical_Co.,_Ltd. |
| gptkbp:website |
www.yiyangpharma.com
|